Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 17


December 8, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day NEXLETOL compared to placebo. “With the announcement of these positive topline results, bempedoic acid becomes the first...